# Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
Canonical URL: https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-updated-biomarker-data-from-phase-1-2-beacon-trial-further-underscoring-risto-cel-s-ability-to-restore-red-blood-cell-health-and-function-in-sickle-cell-disease-at-eha2026
Ticker: BEAM
Company: Beam Therapeutics
Source: Beam Therapeutics
Published: 2026-05-12 13:30 EST
Original Source URL: https://investors.beamtx.com
## Summary

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of

## Article Body
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of
## Recent Company News
- 2026-05-18 20:00 EST — [Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-presents-recently-reported-topline-clinical-data-for-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-american-thoracic-society-ats-2026-international-conference) — Source: Beam Therapeutics
- 2026-05-13 11:00 EST — [Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-at-2026-rbc-capital-markets-global-healthcare-conference) — Source: Beam Therapeutics
- 2026-05-12 13:30 EST — [Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-updated-biomarker-data-from-phase-1-2-beacon-trial-further-underscoring-risto-cel-s-ability-to-restore-red-blood-cell-health-and-function-in-sickle-cell-disease-at-eha2026) — Source: Beam Therapeutics
- 2026-05-07 11:00 EST — [Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates](https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates) — Source: Beam Therapeutics
- 2026-04-01 21:12 EST — [Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine](https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-publication-of-beacon-phase-1-2-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine) — Source: Beam Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)